Acrobiosystems Co

Acrobiosystems Co EBIT per Employee

The EBIT per Employee of Acrobiosystems Co (301080.SZ) as of Nov 16, 2026 is 329,913.99 CNY. In the previous year, EBIT per Employee was 183,110.11 CNY — a change of 80.17% (higher).

EBIT per Employee

329,913.99CNY

YoY

80.17%

Last updated:

EBIT per Employee of Acrobiosystems Co is 2025 329,913.99 CNY. EBIT per Employee of Acrobiosystems Co was 2024 183,110.11 CNY. It decreases by 80.17% higher compared to the previous year.

The Acrobiosystems Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
17,064.82 CNY
Jan 1, 2019
25,532.67 CNY
Jan 1, 2020
234,459.73 CNY
Jan 1, 2021
321,629.13 CNY
Jan 1, 2022
277,434.49 CNY
Jan 1, 2023
221,802.24 CNY
Jan 1, 2024
183,110.11 CNY
Jan 1, 2025
329,913.99 CNY
The Acrobiosystems Co EBIT per Employee history
YEAREBIT per EmployeeYoY
329,913.99CNY+80.17%
183,110.11CNY-17.44%
221,802.24CNY-20.05%
277,434.49CNY-13.74%
321,629.13CNY+37.18%
234,459.73CNY+818.27%
25,532.67CNY+49.62%
17,064.82CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EBIT per Employee of Acrobiosystems Co is 329,913.99 CNY in 2025.

EBIT per Employee of Acrobiosystems Co changed from 183,110.11 CNY to 329,913.99 CNY, representing a 80.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co